← All themes
Theme

Medical Devices

Every analyzed stock in Medical Devices — 253 companies. Each card shows price, our model's intrinsic value (IV), and how far price sits above or below it. Click any card for the full analysis. This is a research-triage view, not a buy/sell signal.

Medical Devices risk
Near-term vs. long-term risk for this theme
⚡ Right now ?Near-term risk over roughly the next 3 months. Blends live market conditions (volatility, how far the S&P is from its highs, credit spreads, the yield curve, sentiment), how stretched valuations are, and what the smart money is doing. Higher = greater odds of a pullback. · next 0–3 months
43 /100 Elevated ▲ +1 slight
Long-term risk ?Long-term / structural risk — the market's underlying tide. Where valuations sit versus 145 years of history (Shiller CAPE) plus multi-year trends. A high reading means weak long-run return prospects even if the market feels calm right now. · structural · vs 145yr history
66 /100 High ▲ +5 mild
▲ / ▼ = change vs ~7 days ago — red = risk rising, green = falling.
Inside the "right now" score — a 45 / 30 / 25 blend · 138 stocks valued
Conditions · 45% ?The live market weather: VIX (expected volatility), how far the S&P 500 is below its 52-week high, high-yield credit spreads, the 10-year vs 2-year yield curve, and the Fear & Greed index. Market-wide indices, not per-stock.
33 Moderate
Valuation · 30% ?How expensive stocks are versus our intrinsic-value models: the median price-to-value ratio and the share of stocks trading above what we think they are worth, across 138 stocks.
51 Elevated
Smart money · 25% ?What informed money is doing: short-selling activity plus corporate insiders buying or selling their own stock. Broken out below.
45 Elevated
Smart money — the three inputs
Short-selling ?Share of ALL US trading volume that is short sales (FINRA, ~12,000 symbols, market-wide). It normally sits near 45–50%, so readings above ~50% lean bearish and read as higher risk. Weighted 40% of Smart money.
49.5%
Elevated
Buyers' strike ?Share of the sampled companies whose insiders bought NONE of their own stock on the open market in the last 12 months. The higher this runs, the more bearish (nobody's buying the dip in their own shares). Weighted 35%.
55%
Elevated
Net insider selling ?Share of the sampled companies whose insiders were net DISCRETIONARY sellers over 12 months (excludes scheduled 10b5-1 plans, which carry little signal). Around half is normal; well above that is bearish. Weighted 25%.
31%
Moderate
Black number = the raw figure; coloured bar & word = how it reads as risk. Insider inputs from 213 stocks (full universe); short-selling is market-wide.
Long-term risk: the long-term read runs high mainly because valuations sit near a historic extreme (Shiller CAPE) — a structural backdrop, not about this week.
Scale (0–100): 0–20 Low · 20–40 Moderate · 40–60 Elevated · 60–80 High · 80–100 Extreme. "Right now" reads today's conditions; the "long-term" score is anchored to ~145 years of valuation history.
Educational use only — not investment advice. "Undervalued / fairly valued / overvalued" and every risk score reflect our models vs. price, which can be wrong or based on stale or incomplete data. Always review the company's own financials and SEC filings, and consult a licensed advisor, before acting.
Sort by: A–Z Riskiest Most overvalued Most shorted Buyers' strike Largest
This week in Medical Devices
Medical Devices — Sep 7 – Sep 11, 2026 (Wk 37): Medical Device Stocks See Elevated Risk Amid Earnings and Valuation Scrutiny →
The medical devices sector experienced an increase in its risk score this week, coinciding with several companies reporting earnings and investors evaluating valuations. While some firms showed profit growth, others faced scrutiny regarding their stock prices…
DOCS
Doximity, Inc.
Undervalued
Technology Risk 25 · Moderate
Price$25.81
Model IV$32.47
P/IV0.66
Discount 21% Return to IV: +25.8%
Market implies +9.5%/yr vs model +15.5% · below model
DRIO
DarioHealth Corp.
Fairly valued
Healthcare Risk 50 · Elevated
Price$6.93
Model IV$7.61
P/IV1.02
Discount 9% Return to IV: +9.8%
Market implies -10.4%/yr vs model +2.2% · below model
DRTS
Alpha Tau Medical Ltd.
Valuation N/A
Healthcare Risk 42 · Elevated
Price$14.43
Model IV—
P/IV—
Limited data — see page
DRTSW
Alpha Tau Medical Ltd.
Valuation N/A
Healthcare Risk 33 · Moderate
Price$3.84
Model IV—
P/IV—
Limited data — see page
DXCM
DEXCOM INC
Fairly valued
Healthcare Risk 41 · Elevated
Price$83.03
Model IV$76.86
P/IV0.96
Premium +8% Return to IV: -7.4%
Market implies +13.8%/yr vs model +16.6% · in line
ECOR
electroCore, Inc.
Valuation N/A
Healthcare Risk 55 · Elevated
Price$9.62
Model IV—
P/IV—
Limited data — see page
EDAP
EDAP TMS SA
Overvalued
Healthcare Risk 56 · Elevated
Price$5.43
Model IV$3.55
P/IV1.22
Premium +53% Return to IV: -34.6%
Market implies -0.8%/yr vs model +15.0% · below model
ELMD
Electromed, Inc.
Deeply overvalued
Healthcare Risk 54 · Elevated
Price$27.25
Model IV$24.49
P/IV1.54
Premium +11% Return to IV: -10.1%
Market implies +11.8%/yr vs model +14.0% · in line
ELMT
Elmet Group Co.
Valuation N/A
Industrials Risk 57 · Elevated
Price$16.19
Model IV—
P/IV—
Limited data — see page
EMBC
Embecta Corp.
Deeply undervalued
Healthcare Risk 34 · Moderate
Price$4.94
Model IV$34.60
P/IV0.10
Discount 86% Return to IV: +600.5%
Market implies -30.4%/yr vs model +3.0% · below model
ENOV
Enovis CORP
Deeply undervalued
Healthcare Risk 29 · Moderate
Price$19.28
Model IV$54.70
P/IV0.41
Discount 65% Return to IV: +183.7%
Market implies -16.6%/yr vs model +12.1% · below model
ESTA
ESTABLISHMENT LABS HOLDINGS INC.
Valuation N/A
Healthcare Risk 68 · High
Price$70.94
Model IV—
P/IV—
Market implies +29.1%/yr vs model +13.6% · above model
EW
Edwards Lifesciences Corp
Deeply overvalued
Healthcare Risk 59 · Elevated
Price$84.37
Model IV$50.87
P/IV1.70
Premium +66% Return to IV: -39.7%
Market implies +12.6%/yr vs model +7.5% · above model
FEED
ENvue Medical, Inc.
Deeply undervalued
Healthcare Risk 33 · Moderate
Price$3.58
Model IV$3.95
P/IV0.23
Discount 9% Return to IV: +10.4%
Market implies -7.8%/yr vs model +10.8% · below model
FEMY
FEMASYS INC
Valuation N/A
Healthcare Risk 29 · Moderate
Price$2.78
Model IV—
P/IV—
Market implies +46.1%/yr vs model +18.1% · above model
FN
Fabrinet
Deeply overvalued
Technology Risk 56 · Elevated
Price$414.58
Model IV$171.24
P/IV3.82
Premium +142% Return to IV: -58.7%
Market implies +20.2%/yr vs model +16.1% · above model
FONR
FONAR CORP
Valuation N/A
Healthcare
Price$19.09
Model IV—
P/IV—
Limited data — see page
FTRE
Fortrea Holdings Inc.
Undervalued
Healthcare Risk 52 · Elevated
Price$17.20
Model IV$18.82
P/IV0.82
Discount 9% Return to IV: +9.4%
Market implies +3.3%/yr vs model +2.0% · in line
FWDI
Forward Industries, Inc.
Valuation N/A
Financial Services Risk 53 · Elevated
Price$6.55
Model IV—
P/IV—
Market implies +21.9%/yr vs model +2.0% · above model
GCTK
Glucotrack, Inc.
Valuation N/A
Healthcare Risk 42 · Elevated
Price$2.27
Model IV—
P/IV—
Limited data — see page
GE
GENERAL ELECTRIC CO
Deeply overvalued
Technology Risk 53 · Elevated
Price$323.66
Model IV$81.24
P/IV3.99
Premium +298% Return to IV: -74.9%
Market implies +22.7%/yr vs model +3.7% · above model
GEHC
GE HealthCare Technologies Inc.
Deeply overvalued
Healthcare Risk 58 · Elevated
Price$63.93
Model IV$47.44
P/IV1.31
Premium +35% Return to IV: -25.8%
Market implies +9.0%/yr vs model +5.9% · above model
GKOS
GLAUKOS Corp
Valuation N/A
Healthcare Risk 42 · Elevated
Price$171.09
Model IV—
P/IV—
Market implies +29.2%/yr vs model +14.6% · above model
GMED
GLOBUS MEDICAL INC
Deeply undervalued
Healthcare Risk 37 · Moderate
Price$75.77
Model IV$183.41
P/IV0.45
Discount 59% Return to IV: +142.1%
Market implies +6.9%/yr vs model +25.0% · below model
GRX
Gabelli Healthcare & WellnessRx Trust
Valuation N/A
Unknown
Price$9.72
Model IV—
P/IV—
Limited data — see page
GUTS
FRACTYL HEALTH, INC.
Valuation N/A
Healthcare Risk 35 · Moderate
Price$0.64
Model IV—
P/IV—
Market implies +98.7%/yr vs model +15.0% · above model
HAE
HAEMONETICS CORP
Deeply undervalued
Healthcare Risk 28 · Moderate
Price$102.69
Model IV$171.50
P/IV0.40
Discount 40% Return to IV: +67.0%
Market implies +1.8%/yr vs model +10.4% · below model
HQH
abrdn Healthcare Investors
Valuation N/A
Unknown
Price$21.76
Model IV—
P/IV—
Limited data — see page
HSCS
HeartSciences Inc.
Valuation N/A
Healthcare Risk 33 · Moderate
Price$3.39
Model IV—
P/IV—
Market implies +93.9%/yr vs model +2.0% · above model
HSCSW
HeartSciences Inc.
Valuation N/A
Financial Services Risk 62 · High
Price$0.07
Model IV—
P/IV—
Market implies +48.8%/yr
HTFL
Heartflow, Inc.
Deeply overvalued
Healthcare Risk 52 · Elevated
Price$49.88
Model IV$12.14
P/IV1.45
Premium +311% Return to IV: -75.7%
Market implies +24.0%/yr vs model +42.1% · below model
HYPR
Hyperfine, Inc.
Deeply overvalued
Healthcare Risk 60 · High
Price$0.80
Model IV$0.42
P/IV3.75
Premium +93% Return to IV: -48.2%
Market implies +14.5%/yr vs model +50.0% · below model
IART
INTEGRA LIFESCIENCES HOLDINGS CORP
Overvalued
Healthcare Risk 54 · Elevated
Price$15.50
Model IV$13.17
P/IV1.22
Premium +18% Return to IV: -15.0%
Market implies +6.2%/yr vs model +2.0% · above model
ICCM
IceCure Medical Ltd.
Valuation N/A
Healthcare Risk 46 · Elevated
Price$2.21
Model IV—
P/IV—
Market implies +92.2%/yr vs model +2.0% · above model
ICLR
ICON PLC
Deeply undervalued
Industrials Risk 32 · Moderate
Price$169.31
Model IV$399.30
P/IV0.34
Discount 58% Return to IV: +135.8%
Market implies +5.7%/yr vs model +23.6% · below model
ICU
SeaStar Medical Holding Corp
Valuation N/A
Healthcare Risk 29 · Moderate
Price$3.03
Model IV—
P/IV—
Market implies +13.7%/yr vs model +15.0% · in line
ICUCW
SeaStar Medical Holding Corp
Valuation N/A
Healthcare Risk 29 · Moderate
Price$0.02
Model IV—
P/IV—
Market implies -50.0%/yr vs model +15.0% · below model
ICUI
ICU MEDICAL INC/DE
Deeply overvalued
Healthcare Risk 63 · High
Price$155.88
Model IV$50.94
P/IV2.66
Premium +206% Return to IV: -67.3%
Market implies +25.4%/yr vs model +12.9% · above model
INBS
INTELLIGENT BIO SOLUTIONS INC.
Deeply overvalued
Healthcare Risk 54 · Elevated
Price$2.13
Model IV$0.66
P/IV3.89
Premium +223% Return to IV: -69.0%
Market implies +9.1%/yr vs model +11.4% · in line
INFU
InfuSystem Holdings, Inc
Fairly valued
Healthcare Risk 40 · Elevated
Price$12.15
Model IV$10.28
P/IV0.88
Premium +18% Return to IV: -15.4%
Market implies +8.6%/yr vs model +10.3% · in line
INGN
Inogen Inc
Deeply undervalued
Healthcare Risk 32 · Moderate
Price$5.31
Model IV$9.60
P/IV0.68
Discount 45% Return to IV: +80.7%
Market implies -12.7%/yr vs model +2.0% · below model
INMD
InMode Ltd.
Deeply undervalued
Healthcare Risk 37 · Moderate
Price$14.89
Model IV$21.34
P/IV0.65
Discount 30% Return to IV: +43.3%
Market implies +0.5%/yr vs model +7.6% · below model
INSP
Inspire Medical Systems, Inc.
Deeply undervalued
Healthcare Risk 32 · Moderate
Price$73.00
Model IV$180.13
P/IV0.23
Discount 59% Return to IV: +146.8%
Market implies -16.3%/yr vs model +40.6% · below model
IQV
IQVIA HOLDINGS INC.
Deeply overvalued
Industrials Risk 51 · Elevated
Price$265.67
Model IV$168.95
P/IV1.08
Premium +57% Return to IV: -36.4%
Market implies +12.5%/yr vs model +7.6% · above model
IRMD
IRADIMED CORP
Deeply overvalued
Healthcare Risk 52 · Elevated
Price$82.53
Model IV$37.26
P/IV2.43
Premium +122% Return to IV: -54.9%
Market implies +22.0%/yr vs model +16.3% · above model
IRTC
iRhythm Holdings, Inc.
Fairly valued
Healthcare Risk 49 · Elevated
Price$111.43
Model IV$106.15
P/IV1.07
Premium +5% Return to IV: -4.7%
Market implies -4.6%/yr vs model +23.3% · below model
ISRG
INTUITIVE SURGICAL INC
Deeply overvalued
Healthcare Risk 58 · Elevated
Price$377.94
Model IV$135.74
P/IV3.13
Premium +178% Return to IV: -64.1%
Market implies +24.3%/yr vs model +13.7% · above model
ITGR
Integer Holdings Corp
Deeply overvalued
Healthcare Risk 49 · Elevated
Price$126.00
Model IV$66.32
P/IV1.35
Premium +90% Return to IV: -47.4%
Market implies +16.8%/yr vs model +10.7% · above model
ITOC
iTonic Holdings Ltd
Valuation N/A
Healthcare Risk 33 · Moderate
Price$0.30
Model IV—
P/IV—
Market implies +56.3%/yr vs model +2.0% · above model
IVF
INVO Fertility, Inc.
Valuation N/A
Healthcare Risk 43 · Elevated
Price$0.97
Model IV—
P/IV—
Market implies -50.0%/yr vs model +50.0% · below model
JNJ
JOHNSON & JOHNSON
Overvalued
Healthcare Risk 49 · Elevated
Price$267.20
Model IV$223.02
P/IV1.18
Premium +20% Return to IV: -16.5%
Market implies +8.4%/yr vs model +7.3% · in line
KIDS
ORTHOPEDIATRICS CORP
Undervalued
Healthcare Risk 39 · Moderate
Price$22.06
Model IV$24.07
P/IV0.71
Discount 8% Return to IV: +9.1%
Market implies -3.4%/yr vs model +24.6% · below model
KMTS
KESTRA MEDICAL TECHNOLOGIES, LTD.
Deeply overvalued
Healthcare Risk 57 · Elevated
Price$22.85
Model IV$9.40
P/IV2.26
Premium +143% Return to IV: -58.9%
Market implies +15.8%/yr vs model +50.0% · below model
KRMD
KORU Medical Systems, Inc.
Deeply overvalued
Healthcare Risk 57 · Elevated
Price$3.16
Model IV$2.18
P/IV1.86
Premium +45% Return to IV: -30.9%
Market implies -1.8%/yr vs model +15.0% · below model
LAKE
LAKELAND INDUSTRIES INC
Deeply undervalued
Healthcare Risk 34 · Moderate
Price$10.38
Model IV$34.48
P/IV0.31
Discount 70% Return to IV: +232.2%
Market implies -24.0%/yr vs model +15.0% · below model
LFCR
LIFECORE BIOMEDICAL, INC. DE
Deeply overvalued
Healthcare Risk 74 · High
Price$4.12
Model IV$2.86
P/IV1.75
Premium +44% Return to IV: -30.5%
Market implies +1.7%/yr vs model +6.3% · below model
LFWD
Lifeward Ltd.
Valuation N/A
Healthcare Risk 31 · Moderate
Price$7.12
Model IV—
P/IV—
Market implies +33.8%/yr vs model +2.0% · above model
LINK
INTERLINK ELECTRONICS INC
Deeply overvalued
Technology Risk 50 · Elevated
Price$5.61
Model IV$1.38
P/IV3.90
Premium +307% Return to IV: -75.5%
Market implies +19.6%/yr vs model +12.3% · above model
LIVN
LivaNova PLC
Deeply overvalued
Healthcare Risk 57 · Elevated
Price$78.18
Model IV$44.42
P/IV1.66
Premium +76% Return to IV: -43.2%
Market implies +14.5%/yr vs model +8.3% · above model
LMAT
LEMAITRE VASCULAR INC
Fairly valued
Healthcare Risk 47 · Elevated
Price$80.59
Model IV$92.60
P/IV1.02
Discount 13% Return to IV: +14.9%
Market implies +7.5%/yr vs model +11.9% · below model